Treace Medical Concepts, Inc. Cash and Cash Equivalents, Period Increase (Decrease)
Treace Medical Concepts, Inc. (TMCI) reported Cash and Cash Equivalents, Period Increase (Decrease) of -$7.35 million for the 3-month period ending 2022-03-31, per its 10-Q filed 2022-05-06.
Discontinued › Cash Flow
us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease · last filed 2022-05-06
- Treace Medical Concepts, Inc. cash and cash equivalents, period increase (decrease) for the quarter ending 2022-03-31 was -$7.35M.
- Treace Medical Concepts, Inc. cash and cash equivalents, period increase (decrease) for the quarter ending 2021-12-31 was -$3.63M, a 235.15% decline year-over-year.
- Treace Medical Concepts, Inc. cash and cash equivalents, period increase (decrease) for the quarter ending 2021-09-30 was -$10.16M, a 299.61% decline year-over-year.
- Treace Medical Concepts, Inc. cash and cash equivalents, period increase (decrease) for the quarter ending 2021-06-30 was $103.40M.
- Treace Medical Concepts, Inc. cash and cash equivalents, period increase (decrease) for fiscal 2021 was $87.75M, a 1377.34% increase from fiscal 2020.
- Treace Medical Concepts, Inc. cash and cash equivalents, period increase (decrease) for fiscal 2020 was $5.94M, a 45.28% decline from fiscal 2019.
- Treace Medical Concepts, Inc. cash and cash equivalents, period increase (decrease) for fiscal 2019 was $10.86M.
| Period end | Cash and Cash Equivalents, Period Increase (Decrease) 3 month | Cash and Cash Equivalents, Period Increase (Decrease) 6 month | Cash and Cash Equivalents, Period Increase (Decrease) 9 month | Cash and Cash Equivalents, Period Increase (Decrease) 12 month |
|---|---|---|---|---|
| 2022-03-31 | -$7.35M 10-Q · filed 2022-05-06 | -$10.98M derived: sum of 2 quarters · filed 2022-05-06 | -$21.14M derived: sum of 3 quarters · filed 2022-05-06 | $82.27M derived: sum of 4 quarters · filed 2022-05-06 |
| 2021-12-31 | -$3.63M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-04 | -$13.79M derived: sum of 2 quarters · filed 2022-03-04 | $89.61M derived: sum of 3 quarters · filed 2022-03-04 | $87.75M 10-K · filed 2022-03-04 |
| 2021-09-30 | -$10.16M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-04 | $93.24M derived: sum of 2 quarters · filed 2021-11-04 | $91.38M 10-Q · filed 2021-11-04 | $94.06M derived: sum of 4 quarters · filed 2022-05-06 |
| 2021-06-30 | $103.40M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-05 | $101.54M 10-Q · filed 2021-08-05 | $104.22M derived: sum of 3 quarters · filed 2022-05-06 | $109.32M derived: sum of 4 quarters · filed 2022-05-06 |
| 2021-03-31 | -$1.86M 10-Q · filed 2022-05-06 | $822.00K derived: sum of 2 quarters · filed 2022-05-06 | $5.91M derived: sum of 3 quarters · filed 2022-05-06 | $5.62M derived: sum of 4 quarters · filed 2022-05-06 |
| 2020-12-31 | $2.68M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-04 | $7.77M derived: sum of 2 quarters · filed 2022-03-04 | $7.48M derived: sum of 3 quarters · filed 2022-03-04 | $5.94M 10-K · filed 2022-03-04 |
| 2020-09-30 | $5.09M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-04 | $4.79M derived: sum of 2 quarters · filed 2021-11-04 | $3.26M 10-Q · filed 2021-11-04 | |
| 2020-06-30 | -$298.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-05 | -$1.83M 10-Q · filed 2021-08-05 | ||
| 2020-03-31 | -$1.54M 10-Q · filed 2021-05-25 | |||
| 2019-12-31 | $10.86M 10-K · filed 2022-03-04 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Mobia Medical, Inc. (MOBI) | United States | $0.293B | |
| TriSalus Life Sciences, Inc. (TLSI) | United States | $0.283B | -9.92 |
| Embecta Corp. (EMBC) | United States | $0.319B | 2.10 |
| Cytosorbents Corp (CTSO) | United States | $0.274B | -1.29 |
| ORASURE TECHNOLOGIES INC (OSUR) | United States | $0.272B | -6.26 |
| Anika Therapeutics, Inc. (ANIK) | United States | $0.272B | -51.71 |
| InfuSystem Holdings, Inc (INFU) | United States | $0.253B | 22.52 |
| UTAH MEDICAL PRODUCTS INC (UTMD) | United States | $0.238B | 20.93 |
| SHOULDER INNOVATIONS, INC. (SI) | United States | $0.355B | |
| Orchestra BioMed Holdings, Inc. (OBIO) | United States | $0.356B | -4.39 |